The PennZone

  • Home
  • Business
  • Health
  • Education
  • Construction
  • Financial
  • Legal
  • Entertainment
  • Books

Braeden Lichti: The Complicated World of Biotech Investments in the Era of COVID-19
The PennZone/10069294

Trending...
  • VIP Vacations Recognized as a 2024 Top Selling Travel Agency by the Jamaica Tourism Board
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
VANCOUVER, British Columbia - PennZone -- Investors are excited about biotechnology stocks in the time of the novel coronavirus.  The Wall Street Journal reports that small and medium biotech stocks are near record highs, with a 60% resurgence in value since March.

Indeed, the time is ripe for biotech companies to cash in on COVID-19 via pursuit of novel drug therapies and vaccines for the condition, which currently has no cure.  But risky biotech companies are taking advantage of the COVID-19 market in an effort to gain more investors for pharma products which may ultimately fail.

Sources of Risk in Biotech and Pharma

The biotech industry is notorious for its high risk, so in a COVID-19 world, more than ever, investors need to look for long-term value from prospective biotech investments.  Sources of risk in the biotechnology and pharma industry – even before the current environment – include:
  • Companies' acquisition by other companies
    Biotech is a fast-paced and dynamic world, and companies may join forces to work on a shared goal.  GlaxoSmithKline has acquired 21 companies over the past decade alone, according to Crunchbase. In an alternative scenario, two companies may race towards a cure, with one company inevitably losing out.

  • Drugs failing in clinical trials after seeming promising in the preclinical world
    While it may take ten years just for a drug to enter the clinical trials process from the laboratory, this protracted timeframe may not spell success.  In 2019, Merck's cancer immunotherapy Keytruda, one of the company's strongest drugs, failed in Phase 3 clinical trials for treatment of a specific type of liver cancer.  Also in 2019, Bristol Myers Squibb's Obdivo failed in a Phase 3 brain cancer trial.

    More on The PennZone
    • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
    • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
    • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
    • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
    • Together We Dance Foundation and Newtown Athletic Club Unite for Inclusive Swim Party

  • Adverse effects which cause drugs to promptly be pulled off the market
    In 2004, Merck recalled another blockbuster drug, the painkiller Vioxx, after patients began suffering heart attacks and strokes.
Investors Should Seek to Minimize Risk in Biotech by Avoiding COVID-19 Hype

A key aspect of investing in biotech has always been to minimize the inherent risk as much as possible.  This means looking at the company's foundation and whether they are an established leader in the field.  Instead of examining how companies are faring in the COVID-19 world, consider tried-and-true leaders in pharma and biotech, which are likely to play a major effort in COVID-19 due to their leadership in the space.

Opting for low-risk stocks which performed well before the economic downturn associated with the ongoing pandemic can help improve the success of your portfolio in the long term.  These companies include:
  • Johnson and Johnson (JNJ), a company with $82.8 billion in sales, which recently announced work on a COVID-19 vaccine and is listed at #34 in Forbes Global 2000 2020.

  • Abbott Labs (ABT), which recently unveiled 5-minute point-of-care testing for the novel coronavirus which can be used at pharmacies and doctor's offices.  Upon this news, the stock price rose nearly 50% from its low price of approximately $69 during the lowest point of the economic downturn to about $90 per share.

    More on The PennZone
    • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
    • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
    • Beyond Spots & Dots Wins Creative Awards for Marketing Initiatives
    • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
    • Solution for Broken Honda Keys: All City Locksmith Launches Durable, Break-Resistant Replacements

  • Gilead Sciences (GLD), a company listed at #186 in the Forbes Global 2000 2020, which recently experienced new popularity as its antiviral treatment, Remdesivir, obtained fast-track FDA approval as a treatment for COVID-19.

  • Pharma giant AstraZeneca (AZN) recently announced a landmark agreement with Oxford University towards making a COVID-19 vaccine a reality for millions around the world.
Other low-risk choices include Pfizer (PFE), GlaxoSmithKine (GSK), and Novartis (NVS).  These biotech and pharma companies have weathered many storms, and, regardless of their contributions to COVID-19, will likely continue to thrive due to their successes elsewhere in the industry.

The Bottom Line

Biotech investors should focus on long-term investing strategies with proven, big pharma companies.  They should avoid small, undercapitalized biotech companies that are simply chasing trends.

Source: Braeden Lichti

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Franchise-Ready: Wise Business Plans Partners with Leading Franchisors to Support New Franchisees
  • VIP Vacations Recognized as a 2024 Top Selling Travel Agency by the Jamaica Tourism Board
  • Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Colbert Packaging Announces WBENC Recognition
  • SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
  • Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments

Popular on PennZone

  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN) - 112
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • New Bethany Acquires Former Diocesan Headquarters to Expand Services
  • Bethany Nikitenko Honored By Legal Intelligencer with Power Player Award
  • JOSHWAY Launches Children's Book, "JOSHWAY and the Power of Resilience"
  • Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
  • KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
  • Jeopardy!'s Ken Jennings Headlines National Mensa Event
  • Coming Soon: The Cottages at Powell Park Offer a Rare Blend of Charm, Convenience, and Community in Raleigh

Similar on PennZone

  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
  • Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us